FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279408238> ?p ?o ?g. }

• W2279408238 endingPage "206" @default.
• W2279408238 startingPage "194" @default.
• W2279408238 abstract "Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. Despite over 50 years of experience in this setting, certain aspects of the use of this drug in clinical practice are still little standardized and poorly understood. For this reason, a group of 15 experts took part in a consensus development conference to achieve consensus on a series of recommendations on the use of MTX in psoriasis. The guidelines, which were developed on the basis of a systematic review of the literature, were validated by 2 rounds of voting and categorized by level of evidence and grade of recommendation. Before MTX can be used to treat moderate to severe psoriasis, the patient must be evaluated to assess the suitability of the treatment, including consideration of vaccination status and screening for tuberculosis and pregnancy. The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is 20 mg/wk. Most patients who respond to treatment will show improvement within 8 weeks. Parenteral administration of MTX is desirable when there is a risk of erroroneous dosing, nonadherence, gastrointestinal intolerance, or inadequate response to the therapeutic dose taken orally. Noninvasive methods are preferred for monitoring hepatotoxicity. MTX is a good treatment option for patients with a history of cancer, but is not recommended in patients with chronic hepatitis B infection or individuals who are seropositive for human immunodeficiency virus. Metotrexato (MTX) es el fármaco sistémico convencional más empleado en el tratamiento de la psoriasis. A pesar de que la experiencia en su uso se remonta a más de 50 años, todavía existen aspectos en el manejo clínico poco estandarizados o conocidos. Bajo esta premisa, un grupo de 15 expertos participó en una conferencia de consenso en la que, a partir de una revisión sistemática y 2 rondas de validación previas, se validaron recomendaciones categorizadas por nivel de evidencia y grado de recomendación sobre el uso de MTX en la psoriasis. La elección de MTX en el tratamiento de la psoriasis moderada grave requiere la evaluación previa de la idoneidad del fármaco, incluyendo estado de vacunación, cribado de tuberculosis y gestación. La dosis recomendada de inicio es de 10–20 mg/semana si el paciente no presenta factores de riesgo, con una dosis terapéutica de 15 mg/semana para la mayoría de pacientes y máxima de 20 mg/semana. La mayor parte de pacientes que respondan al tratamiento mostrarán mejoría antes de las 8 semanas. Es preferible la administración parenteral de MTX cuando exista riesgo de error en la pauta de administración, incumplimiento, intolerancia gastrointestinal o respuesta insuficiente a dosis plenas por vía oral. Los métodos no invasivos son preferibles para la monitorización de la hepatotoxicidad. El tratamiento con MTX representa una buena opción en pacientes con antecedentes oncológicos, mientras que no se recomienda en pacientes portadores crónicos de virus de la hepatitis B o seropositivos para el virus de la inmunodeficiencia humana (VIH+)." @default.
• W2279408238 created "2016-06-24" @default.
• W2279408238 creator A5001891568 @default.
• W2279408238 creator A5001984863 @default.
• W2279408238 creator A5008022026 @default.
• W2279408238 creator A5012897301 @default.
• W2279408238 creator A5028252915 @default.
• W2279408238 creator A5029522345 @default.
• W2279408238 creator A5032484568 @default.
• W2279408238 creator A5033015474 @default.
• W2279408238 creator A5034720013 @default.
• W2279408238 creator A5043601433 @default.
• W2279408238 creator A5067901169 @default.
• W2279408238 creator A5082165528 @default.
• W2279408238 creator A5084023178 @default.
• W2279408238 creator A5086044597 @default.
• W2279408238 creator A5091668600 @default.
• W2279408238 date "2016-04-01" @default.
• W2279408238 modified "2023-10-02" @default.
• W2279408238 title "Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations" @default.
• W2279408238 cites W1482577753 @default.
• W2279408238 cites W1541913191 @default.
• W2279408238 cites W1581115144 @default.
• W2279408238 cites W1591809044 @default.
• W2279408238 cites W1696546567 @default.
• W2279408238 cites W1882277951 @default.
• W2279408238 cites W1901883624 @default.
• W2279408238 cites W1966811010 @default.
• W2279408238 cites W1976717494 @default.
• W2279408238 cites W1987487114 @default.
• W2279408238 cites W1991441381 @default.
• W2279408238 cites W1992204505 @default.
• W2279408238 cites W1996773947 @default.
• W2279408238 cites W1998450075 @default.
• W2279408238 cites W2010981833 @default.
• W2279408238 cites W2019737522 @default.
• W2279408238 cites W2022225387 @default.
• W2279408238 cites W2024261468 @default.
• W2279408238 cites W2025498802 @default.
• W2279408238 cites W2030605573 @default.
• W2279408238 cites W2031602795 @default.
• W2279408238 cites W2033889161 @default.
• W2279408238 cites W2046454438 @default.
• W2279408238 cites W2047777043 @default.
• W2279408238 cites W2054211760 @default.
• W2279408238 cites W2057289604 @default.
• W2279408238 cites W2058697685 @default.
• W2279408238 cites W2069350424 @default.
• W2279408238 cites W2081998146 @default.
• W2279408238 cites W2085076100 @default.
• W2279408238 cites W2087722290 @default.
• W2279408238 cites W2093370279 @default.
• W2279408238 cites W2094739606 @default.
• W2279408238 cites W2098798511 @default.
• W2279408238 cites W2121588356 @default.
• W2279408238 cites W2125574445 @default.
• W2279408238 cites W2137760756 @default.
• W2279408238 cites W2140101720 @default.
• W2279408238 cites W2141395406 @default.
• W2279408238 cites W2145803164 @default.
• W2279408238 cites W2149118348 @default.
• W2279408238 cites W2154829710 @default.
• W2279408238 cites W2155123856 @default.
• W2279408238 cites W2156449368 @default.
• W2279408238 cites W2157004194 @default.
• W2279408238 cites W2158176886 @default.
• W2279408238 cites W2158489950 @default.
• W2279408238 cites W2158506827 @default.
• W2279408238 cites W2163232748 @default.
• W2279408238 cites W2167148209 @default.
• W2279408238 cites W2170981231 @default.
• W2279408238 cites W2321934992 @default.
• W2279408238 cites W4246398917 @default.
• W2279408238 cites W4376849728 @default.
• W2279408238 doi "https://doi.org/10.1016/j.adengl.2016.01.025" @default.
• W2279408238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26614486" @default.
• W2279408238 hasPublicationYear "2016" @default.
• W2279408238 type Work @default.
• W2279408238 sameAs 2279408238 @default.
• W2279408238 citedByCount "8" @default.
• W2279408238 countsByYear W22794082382016 @default.
• W2279408238 countsByYear W22794082382017 @default.
• W2279408238 countsByYear W22794082382018 @default.
• W2279408238 countsByYear W22794082382019 @default.
• W2279408238 countsByYear W22794082382020 @default.
• W2279408238 countsByYear W22794082382023 @default.
• W2279408238 crossrefType "journal-article" @default.
• W2279408238 hasAuthorship W2279408238A5001891568 @default.
• W2279408238 hasAuthorship W2279408238A5001984863 @default.
• W2279408238 hasAuthorship W2279408238A5008022026 @default.
• W2279408238 hasAuthorship W2279408238A5012897301 @default.
• W2279408238 hasAuthorship W2279408238A5028252915 @default.
• W2279408238 hasAuthorship W2279408238A5029522345 @default.
• W2279408238 hasAuthorship W2279408238A5032484568 @default.
• W2279408238 hasAuthorship W2279408238A5033015474 @default.
• W2279408238 hasAuthorship W2279408238A5034720013 @default.
• W2279408238 hasAuthorship W2279408238A5043601433 @default.
• W2279408238 hasAuthorship W2279408238A5067901169 @default.

• next